Last reviewed · How we verify
Probiotic Supplement
Probiotic supplements introduce beneficial live microorganisms into the gastrointestinal tract to promote a healthy microbiome balance.
Probiotic supplements introduce beneficial live microorganisms into the gastrointestinal tract to promote a healthy microbiome balance. Used for Digestive health support, Gastrointestinal microbiome balance.
At a glance
| Generic name | Probiotic Supplement |
|---|---|
| Also known as | Probio-Tec® BG-VCap-6.5 |
| Sponsor | Sheppard Pratt Health System |
| Drug class | Probiotic supplement |
| Modality | Biologic |
| Therapeutic area | Gastroenterology / Immunology |
| Phase | FDA-approved |
Mechanism of action
Probiotics are live bacteria and/or yeasts that colonize the gut and compete with pathogenic organisms for nutrients and adhesion sites. They produce short-chain fatty acids, enhance intestinal barrier function, and modulate immune responses through interaction with gut-associated lymphoid tissue. This restoration of microbial balance may improve digestive health, reduce inflammation, and support overall immune function.
Approved indications
- Digestive health support
- Gastrointestinal microbiome balance
Common side effects
- Bloating
- Gas
- Mild gastrointestinal discomfort
Key clinical trials
- Effects of Probiotics on Respiratory Tract Infections in Children: A Randomized, Placebo-Controlled Interventional Study (PHASE2)
- Probiotic Intervention Study (NA)
- The Intervention of Obesity in Children With Prader-Willi Syndrome Using Prebiotics and Probiotics (NA)
- The Effects of a Probiotic Food Supplement in Hyperuricaemia (NA)
- The Gut - PRO Study (PHASE2)
- Precision Nutrition Recommendations Generated by Metataxonomic Microbiome Testing Improve Food Group Choices and Intestinal Health Indicators in an Obese Population in Colombia (NA)
- Evaluation of the Ability of Lactobacillus Crispatus CRP21 to Reduce the Incidence of Recurrent Bacterial Vaginosis (NA)
- To Investigate the Effects of Bifidobacterium Animalis Subsp. Lactis XLTG11 on Growth and Development, Incidence of Allergy and Immune Function in Infants (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Probiotic Supplement CI brief — competitive landscape report
- Probiotic Supplement updates RSS · CI watch RSS
- Sheppard Pratt Health System portfolio CI